Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.55 |
| ▸ | F3 | P13726 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.49 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28847710 | 0.86 | F7 (0.61) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL24630105 | 0.85 | NR4A2 (0.54) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL30386394 | 0.84 | F7 (0.55) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL24996259 | 0.84 | NR4A2 (0.49) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL12545431 | 0.84 | NR4A2 (0.52) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL23167610 | 0.83 | F7 (0.58) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL25024359 | 0.83 | NPSR1 (0.56) | HSD17B10KDM4ETSHR | |
| SCHEMBL30233531 | 0.83 | NPSR1 (0.56) | HSD17B10KDM4ETSHR | |
| SCHEMBL23207500 | 0.82 | NR4A2 (0.58) | MTNR1AMTNR1BNR4A2F7F3 | |
| SCHEMBL24997127 | 0.82 | NR4A2 (0.47) | MTNR1AMTNR1BNR4A2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MTNR1A 3742/4885MTNR1B 3276/4885NR4A2 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.